Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Canada
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
FDF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 3-(trans-4-(2-(4-(2,3-dichlorophenyl)piperazin-1-yl)ethyl)cyclohexyl)-1,1-dimethylurea
2. Cariprazine
3. Cariprazine Hcl
4. N'-(trans-4-(2-(4-(2,3-dichlorophenyl)piperazin-1-yl)ethyl)cyclohexyl)-n,n-dimethylurea Monohydrochloride
5. Rgh-188
6. Trans-4-(2-(4-(2,3-dichlorophenyl)piperazine-1-yl)-ethyl)-n,n-dimethylcarbamoyl-cyclohexyl-amine Hydrochloride
7. Vraylar
1. 1083076-69-0
2. Cariprazine Hcl
3. Vraylar
4. Rgh188 Hydrochloride
5. Rgh-188 Hcl
6. Cariprazine (hydrochloride)
7. Cariprazine Hydrochloride [usan]
8. Kqd7c255yg
9. Mfcd26142670
10. 3-[4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-1,1-dimethylurea;hydrochloride
11. Unii-kqd7c255yg
12. Cariprazine.hcl
13. Vraylar (tn)
14. Cariprazine Hydrochloride (jan/usan)
15. Cariprazine Monohydrochloride
16. Schembl183803
17. Schembl183804
18. Chembl2024517
19. Chebi:90932
20. Dtxsid101026486
21. Bcp24194
22. Ex-a1644
23. Hy-14763a
24. S5849
25. Cariprazine Hydrochloride [mi]
26. Cariprazine Hydrochloride [jan]
27. Cs-1570
28. Sb16840
29. 3-[trans-4-[2-[4-(2,3-dichlorophenyl)-1-piperazinyl]ethyl]cyclohexyl]-1,1-dimethylurea Hydrochloride
30. Ac-33130
31. Cariprazine Hydrochloride [who-dd]
32. Sy039271
33. Ft-0701196
34. A15036
35. Cariprazine Hydrochloride [orange Book]
36. D09876
37. A857936
38. Q27162922
39. 3-((1r,4r)-4-(2-(4-(2,3-dichlorophenyl)piperazin-1-yl)ethyl)cyclohexyl)-1,1-dimethylurea Hydrochloride
40. N'-(trans-4-(2-(4-(2,3-dichlorophenyl)piperazin-1-yl)ethyl)cyclohexyl)-n,n-dimethylurea Monohydrochloride
41. N'-(trans-4-(2-(4-(2,3-dichlorophenyl)piperazin-1-yl)ethyl)cyclohexyl)-n,n-dimthylurea Monohydrochloride
42. N'-(trans-4-{2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl}cyclohexyl)-n,n-dimethylurea Hydrochloride
43. N'-[trans-4-[2-[4-(2,3-dichlorophenyl)-1-piperazinyl]ethyl]cyclohexyl]-n,n-dimethylurea Hydrochloride
44. Urea, N'-(trans-4-(2-(4-(2,3-dichlorophenyl)-1-piperazinyl)ethyl)cyclohexyl)-n,n- Dimethyl-, Hydrochloride (1:1)
Molecular Weight | 463.9 g/mol |
---|---|
Molecular Formula | C21H33Cl3N4O |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 3 |
Rotatable Bond Count | 5 |
Exact Mass | 462.171995 g/mol |
Monoisotopic Mass | 462.171995 g/mol |
Topological Polar Surface Area | 38.8 Ų |
Heavy Atom Count | 29 |
Formal Charge | 0 |
Complexity | 491 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Reagila is indicated for the treatment of schizophrenia in adult patients.
Treatment of schizophrenia
Antipsychotic Agents
Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)
N05AX15
Delivering Quality APIs, Drug Intermediates, and Specialty Chemicals to Over 50 Countries Across the Globe.
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 33846
Submission : 2019-05-30
Status : Active
Type : II
Shanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.
Honour is a leading global CDMO and specialty chemicals manufacturer with seven world-class sites delivering quality-driven solutions.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 38749
Submission : 2023-09-14
Status : Active
Type : II
Date of Issue : 2022-06-15
Valid Till : 2025-07-28
Written Confirmation Number : WC-0186
Address of the Firm :
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 26321
Submission : 2012-07-26
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2023-11-14
Pay. Date : 2023-09-27
DMF Number : 38933
Submission : 2023-09-26
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 41156
Submission : 2025-02-14
Status : Active
Type : II
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 33846
Submission : 2019-05-30
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2019-07-23
Pay. Date : 2019-06-26
DMF Number : 33956
Submission : 2019-06-26
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 26321
Submission : 2012-07-26
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 38749
Submission : 2023-09-14
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2019-08-14
Pay. Date : 2019-03-15
DMF Number : 33623
Submission : 2019-03-22
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 33399
Submission : 2018-12-14
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 41156
Submission : 2025-02-14
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2025-03-27
Pay. Date : 2025-03-24
DMF Number : 41312
Submission : 2025-03-14
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2019-07-31
Pay. Date : 2019-07-18
DMF Number : 33834
Submission : 2019-07-18
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2023-11-14
Pay. Date : 2023-09-27
DMF Number : 38933
Submission : 2023-09-26
Status : Active
Type : II
Date of Issue : 2022-06-07
Valid Till : 2025-06-25
Written Confirmation Number : WC-0023
Address of the Firm : Survey no. 52,53,58,59,61 to 78,127&128, Pydibhimanvaram Village &Sy.No. 1,2,4t0...
Date of Issue : 2022-06-15
Valid Till : 2025-07-28
Written Confirmation Number : WC-0186
Address of the Firm : Sy No.10/G-1, Gaddapotharam (V), Jinnaram (M), Sangareddy District, Pincode 5023...
Date of Issue : 2023-11-15
Valid Till : 2026-05-11
Written Confirmation Number : WC-0273
Address of the Firm : Plot No: 34A, Road No: 1, Jawaharlal Nehru Pharma City, Thanam Village, Parawada...
Date of Issue : 2022-08-08
Valid Till : 2025-07-14
Written Confirmation Number : WC-0168
Address of the Firm : Plot No. 24/2, & 25, Phase -IV, GIDC Industrial Zone, At & Post - Panoli, Dist.-...
NDC Package Code : 59651-400
Start Marketing Date : 2024-01-18
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (25kg/50kg)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 57741-4100
Start Marketing Date : 2024-09-27
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 57741-3700
Start Marketing Date : 2015-07-17
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 14501-0035
Start Marketing Date : 2018-12-13
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 76055-0042
Start Marketing Date : 2019-07-25
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 82708-0003
Start Marketing Date : 2015-09-17
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
VRAYLAR (cariprazine) is an oral, once-daily atypical antipsychotic approved as an adjunctive therapy to antidepressants for the treatment of major depressive disorder in adults (1.5 or 3 mg/day), for the treatment of depressive episodes associated with bipolar I disorder.
Lead Product(s): Cariprazine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: Vraylar
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 16, 2022
Lead Product(s) : Cariprazine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
U.S. FDA Approves VRAYLAR® (cariprazine) as an Adjunctive Treatment for Major Depressive Disorder
Details : VRAYLAR (cariprazine) is an oral, once-daily atypical antipsychotic approved as an adjunctive therapy to antidepressants for the treatment of major depressive disorder in adults (1.5 or 3 mg/day), for the treatment of depressive episodes associated with ...
Product Name : Vraylar
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 16, 2022
Details:
In Study 3111-301-001, cariprazine (VRAYLAR®; 1.5mg/day) achieved the primary endpoint of statistically significant improvement on MADRS total score in patients with major depressive disorder with an inadequate response to ongoing antidepressant therapy.
Lead Product(s): Cariprazine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: Vraylar
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 23, 2022
Lead Product(s) : Cariprazine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AbbVie Presents Positive Data from Phase 3 Study of Cariprazine (VRAYLAR®) for the Adjunctive Tre...
Details : In Study 3111-301-001, cariprazine (VRAYLAR®; 1.5mg/day) achieved the primary endpoint of statistically significant improvement on MADRS total score in patients with major depressive disorder with an inadequate response to ongoing antidepressant therapy...
Product Name : Vraylar
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 23, 2022
Details:
Submission based on clinical trial results findings showing clinically and statistically significant improvement in the Montgomery-Åsberg Depression Rating Scale total score in patients with major depressive disorder treated with VRAYLAR (cariprazine) and an antidepressant.
Lead Product(s): Cariprazine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: Vraylar
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 22, 2022
Lead Product(s) : Cariprazine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AbbVie Submits Supplemental New Drug Application to U.S. FDA for Cariprazine (VRAYLAR®) for the A...
Details : Submission based on clinical trial results findings showing clinically and statistically significant improvement in the Montgomery-Åsberg Depression Rating Scale total score in patients with major depressive disorder treated with VRAYLAR (cariprazine) a...
Product Name : Vraylar
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 22, 2022
Details:
VRAYLAR® (cariprazine), a partial agonist at dopamine D3, D2, and serotonin 5-HT1A receptors used as atypical antipsychotic, met its primary endpoint demonstrating statistically significant change from baseline to week six in MADRS total score in major depressive disorder.
Lead Product(s): Cariprazine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: Vraylar
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 29, 2021
Lead Product(s) : Cariprazine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AbbVie's Cariprazine (VRAYLAR®) Met Primary Endpoint in Phase 3 Study as an Adjunctive Treatment ...
Details : VRAYLAR® (cariprazine), a partial agonist at dopamine D3, D2, and serotonin 5-HT1A receptors used as atypical antipsychotic, met its primary endpoint demonstrating statistically significant change from baseline to week six in MADRS total score in major ...
Product Name : Vraylar
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 29, 2021
Details:
Tentative approval recieved from USFDA to market Cariprazine-Generic an atypical antipsychotic drug for the treatment of schizophrenia and acute treatment of manic or mixed episodes associated with bipolar disorder.
Lead Product(s): Cariprazine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: Cariprazine-Generic
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 12, 2021
Lead Product(s) : Cariprazine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zydus Cadila Receives Tentative Approval From USFDA for Cariprazine Capsules
Details : Tentative approval recieved from USFDA to market Cariprazine-Generic an atypical antipsychotic drug for the treatment of schizophrenia and acute treatment of manic or mixed episodes associated with bipolar disorder.
Product Name : Cariprazine-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 12, 2021
Regulatory Info : RX
Registration Country : USA
Brand Name : VRAYLAR
Dosage Form : CAPSULE;ORAL
Dosage Strength : EQ 1.5MG BASE
Packaging :
Approval Date : 2015-09-17
Application Number : 204370
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Brand Name : VRAYLAR
Dosage Form : CAPSULE;ORAL
Dosage Strength : EQ 3MG BASE
Packaging :
Approval Date : 2015-09-17
Application Number : 204370
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Brand Name : VRAYLAR
Dosage Form : CAPSULE;ORAL
Dosage Strength : EQ 4.5MG BASE
Packaging :
Approval Date : 2015-09-17
Application Number : 204370
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Brand Name : VRAYLAR
Dosage Form : CAPSULE;ORAL
Dosage Strength : EQ 6MG BASE
Packaging :
Approval Date : 2015-09-17
Application Number : 204370
Regulatory Info : RX
Registration Country : USA
Regulatory Info : Originator
Registration Country : South Africa
Brand Name : Reagila 1,5 mg capsule
Dosage Form : CAP
Dosage Strength : 1.5mg
Packaging : 30X1mg
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa
Regulatory Info :
Registration Country : Switzerland
Brand Name : Reagila
Dosage Form : Caps
Dosage Strength : 1.5mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Brand Name : Reagila
Dosage Form : Caps
Dosage Strength : 3mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Brand Name : Reagila
Dosage Form : Caps
Dosage Strength : 6mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Australia
Brand Name : Reagila
Dosage Form :
Dosage Strength :
Packaging : 30
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info : DISCN
Registration Country : USA
Brand Name : CARIPRAZINE HYDROCHLORIDE
Dosage Form : CAPSULE;ORAL
Dosage Strength : EQ 3MG BASE
Packaging :
Approval Date : 2022-09-30
Application Number : 213932
Regulatory Info : DISCN
Registration Country : USA
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
86
PharmaCompass offers a list of Cariprazine Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Cariprazine Hydrochloride manufacturer or Cariprazine Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Cariprazine Hydrochloride manufacturer or Cariprazine Hydrochloride supplier.
PharmaCompass also assists you with knowing the Cariprazine Hydrochloride API Price utilized in the formulation of products. Cariprazine Hydrochloride API Price is not always fixed or binding as the Cariprazine Hydrochloride Price is obtained through a variety of data sources. The Cariprazine Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Cariprazine Hydrochloride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Cariprazine Hydrochloride, including repackagers and relabelers. The FDA regulates Cariprazine Hydrochloride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Cariprazine Hydrochloride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Cariprazine Hydrochloride manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Cariprazine Hydrochloride supplier is an individual or a company that provides Cariprazine Hydrochloride active pharmaceutical ingredient (API) or Cariprazine Hydrochloride finished formulations upon request. The Cariprazine Hydrochloride suppliers may include Cariprazine Hydrochloride API manufacturers, exporters, distributors and traders.
click here to find a list of Cariprazine Hydrochloride suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Cariprazine Hydrochloride DMF (Drug Master File) is a document detailing the whole manufacturing process of Cariprazine Hydrochloride active pharmaceutical ingredient (API) in detail. Different forms of Cariprazine Hydrochloride DMFs exist exist since differing nations have different regulations, such as Cariprazine Hydrochloride USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Cariprazine Hydrochloride DMF submitted to regulatory agencies in the US is known as a USDMF. Cariprazine Hydrochloride USDMF includes data on Cariprazine Hydrochloride's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Cariprazine Hydrochloride USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Cariprazine Hydrochloride suppliers with USDMF on PharmaCompass.
A Cariprazine Hydrochloride written confirmation (Cariprazine Hydrochloride WC) is an official document issued by a regulatory agency to a Cariprazine Hydrochloride manufacturer, verifying that the manufacturing facility of a Cariprazine Hydrochloride active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Cariprazine Hydrochloride APIs or Cariprazine Hydrochloride finished pharmaceutical products to another nation, regulatory agencies frequently require a Cariprazine Hydrochloride WC (written confirmation) as part of the regulatory process.
click here to find a list of Cariprazine Hydrochloride suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Cariprazine Hydrochloride as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Cariprazine Hydrochloride API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Cariprazine Hydrochloride as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Cariprazine Hydrochloride and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Cariprazine Hydrochloride NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Cariprazine Hydrochloride suppliers with NDC on PharmaCompass.
Cariprazine Hydrochloride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Cariprazine Hydrochloride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Cariprazine Hydrochloride GMP manufacturer or Cariprazine Hydrochloride GMP API supplier for your needs.
A Cariprazine Hydrochloride CoA (Certificate of Analysis) is a formal document that attests to Cariprazine Hydrochloride's compliance with Cariprazine Hydrochloride specifications and serves as a tool for batch-level quality control.
Cariprazine Hydrochloride CoA mostly includes findings from lab analyses of a specific batch. For each Cariprazine Hydrochloride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Cariprazine Hydrochloride may be tested according to a variety of international standards, such as European Pharmacopoeia (Cariprazine Hydrochloride EP), Cariprazine Hydrochloride JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Cariprazine Hydrochloride USP).